Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7393300 | 0.89 | PDE4A (0.52) | PDE4AKCNH2 | |
| SCHEMBL7366254 | 0.86 | PDE4A (0.64) | PDE4AKCNH2 | |
| SCHEMBL7359822 | 0.86 | PDE4A (0.66) | PDE4AKCNH2 | |
| SCHEMBL7366809 | 0.85 | PDE4A (0.64) | PDE4AKCNH2 | |
| SCHEMBL7977050 | 0.82 | PDE4A (0.66) | PDE4AKCNH2 | |
| SCHEMBL7383406 | 0.82 | PDE4A (0.65) | PDE4AKCNH2 | |
| SCHEMBL7905326 | 0.80 | PDE4A (0.71) | PDE4AKCNH2 | |
| SCHEMBL16670019 | 0.80 | PDE4A (0.68) | PDE4AKCNH2 | |
| SCHEMBL7899118 | 0.79 | PDE4A (0.73) | PDE4AKCNH2 | |
| SCHEMBL7376251 | 0.78 | PDE4A (0.67) | PDE4AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | claimed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | claimed |
| US-6316472-B1 | Heterosubstituted pyridine derivatives as PDE 4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2001-11-13 | — | — | US | claimed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | disclosed |
| US-6316472-B1 | Heterosubstituted pyridine derivatives as PDE 4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE4A 1173/4885KCNH2 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.